Skip to main content
I

IMUGENE LIMITED — Investor Relations & Filings

Ticker · IMU ISIN · AU000000IMU9 LEI · 984500A5C9KF08EAF248 ASX Professional, scientific and technical activities
Open in API
Filings indexed 1,426 across all filing types
Latest filing 2026-04-23 Share Issue/Capital Cha…
Country AU Australia
Listing ASX IMU

About IMUGENE LIMITED

https://imugene.com

Imugene Limited is a clinical-stage immuno-oncology company focused on developing immunotherapies to activate the immune system against various cancers. The company’s pipeline features multiple platform technologies, including B-cell activating immunotherapies, oncolytic viruses, and CAR-T cell enhancement therapies. Key clinical candidates include HER-Vaxx, targeting HER2-positive gastric cancer, and PD1-Vaxx, a checkpoint inhibitor immunotherapy. Imugene is also advancing the CF33 oncolytic virus platform, which includes VAXINIA and CHECKvacc, alongside the onCARlytics program. The onCARlytics platform is designed to enable CAR-T cells to target solid tumors by inducing the expression of CD19 on cancer cell surfaces. These programs aim to address unmet needs in oncology by providing targeted, potent, and potentially less toxic alternatives to conventional treatments.

Recent filings

Filing Released Lang Actions
Application for quotation of securities - IMU 8 pages 20.8KB
Share Issue/Capital Change Classification · 1% confidence The document is the ASX Listing Rule Appendix 2A “Application for quotation of securities,” detailing the number and type of newly issued securities to be quoted on the exchange. This is a specific announcement regarding the quotation of new shares (capital change). It is not a full report or earnings release but a listing application, best fitting the “Share Issue/Capital Change” category (SHA).
2026-04-23 English
EGM Results and Share Purchase Plan Final Allotment 5 pages 189.8KB
Declaration of Voting Results & Voting Rights Announcements Classification · 1% confidence The document is an ASX Announcement detailing the results of an Extraordinary General Meeting (EGM) including the poll outcomes for each resolution (proxy vote counts, percentages, and carried outcomes), together with the final share purchase plan allotment. This directly matches the definition of "Declaration of Voting Results & Voting Rights Announcements" (DVA), which covers official shareholder vote results at a general meeting. Although it also describes capital raising details, the primary purpose is to report the formal voting results of the EGM.
2026-04-22 English
Change of Director's Interest Notice -LC 2 pages 5.5KB
Director's Dealing Classification · 1% confidence The document is an ASX Appendix 3Y “Change of Director’s Interest Notice” detailing a director’s acquisition of shares and options under Listing Rule 3.19A.2. It reports a personal share transaction by a company director (insider dealing). This matches the definition for Director’s Dealing (Code: DIRS).
2026-04-21 English
Notification of cessation of securities - IMU 6 pages 20.0KB
Regulatory Filings
2026-04-09 English
Application for quotation of securities - IMU 8 pages 21.1KB
Regulatory Filings
2026-04-07 English
Notification regarding unquoted securities - IMU 8 pages 21.4KB
Regulatory Filings
2026-04-01 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.